NASDAQ:ALPN - Alpine Immune Sciences Stock Price, News & Analysis

$5.00
+0.39 (+8.46 %)
(As of 08/23/2019 04:00 PM ET)
Today's Range
$4.50
Now: $5.00
$5.00
50-Day Range
$3.52
MA: $4.29
$5.16
52-Week Range
$3.41
Now: $5.00
$8.24
Volume588 shs
Average Volume14,634 shs
Market Capitalization$92.85 million
P/E RatioN/A
Dividend YieldN/A
Beta1.88
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALPN
CUSIPN/A
Phone206-788-4545

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$700,000.00
Book Value$2.45 per share

Profitability

Net Income$-36,490,000.00

Miscellaneous

Employees48
Market Cap$92.85 million
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable

Receive ALPN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter.


Alpine Immune Sciences (NASDAQ:ALPN) Frequently Asked Questions

What is Alpine Immune Sciences' stock symbol?

Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences Inc (NASDAQ:ALPN) announced its quarterly earnings data on Tuesday, August, 13th. The biotechnology company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.04. The biotechnology company earned $0.57 million during the quarter, compared to analysts' expectations of $0.25 million. View Alpine Immune Sciences' Earnings History.

When is Alpine Immune Sciences' next earnings date?

Alpine Immune Sciences is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Alpine Immune Sciences.

What price target have analysts set for ALPN?

2 brokers have issued 1 year target prices for Alpine Immune Sciences' stock. Their forecasts range from $12.00 to $13.00. On average, they anticipate Alpine Immune Sciences' share price to reach $12.50 in the next year. This suggests a possible upside of 150.0% from the stock's current price. View Analyst Price Targets for Alpine Immune Sciences.

What is the consensus analysts' recommendation for Alpine Immune Sciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alpine Immune Sciences.

Has Alpine Immune Sciences been receiving favorable news coverage?

News stories about ALPN stock have been trending positive this week, InfoTrie reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Alpine Immune Sciences earned a news sentiment score of 2.5 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the near future. View News Stories for Alpine Immune Sciences.

Who are some of Alpine Immune Sciences' key competitors?

What other stocks do shareholders of Alpine Immune Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alpine Immune Sciences investors own include Viking Therapeutics (VKTX), Abeona Therapeutics (ABEO), Melinta Therapeutics (MLNT), Celgene (CELG), Energy Transfer LP Unit (ET), AEterna Zentaris (AEZS), Progenics Pharmaceuticals (PGNX), Verastem (VSTM), Ardelyx (ARDX) and BIOLINERX LTD/S (BLRX).

Who are Alpine Immune Sciences' key executives?

Alpine Immune Sciences' management team includes the folowing people:
  • Dr. Mitchell H. Gold, Exec. Chairman & CEO (Age 51)
  • Dr. Stanford Peng, Pres and Head of R&D (Age 48)
  • Mr. Paul Rickey, Sr. VP, CFO & Corp. Sec. (Age 40)
  • Dr. Kristine Swiderek Ph.D., Sr. VP of Research

Who are Alpine Immune Sciences' major shareholders?

Alpine Immune Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.09%), Victory Capital Management Inc. (0.71%), Renaissance Technologies LLC (0.57%), Jacobs Levy Equity Management Inc. (0.11%) and Leonard Rickey Investment Advisors P.L.L.C. (0.05%). Company insiders that own Alpine Immune Sciences stock include James N Topper, James Paul Rickey, Mitchell Gold and Tiger Management LLC. View Institutional Ownership Trends for Alpine Immune Sciences.

Which institutional investors are selling Alpine Immune Sciences stock?

ALPN stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc.. View Insider Buying and Selling for Alpine Immune Sciences.

Which institutional investors are buying Alpine Immune Sciences stock?

ALPN stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Jacobs Levy Equity Management Inc., Renaissance Technologies LLC and Leonard Rickey Investment Advisors P.L.L.C.. Company insiders that have bought Alpine Immune Sciences stock in the last two years include James N Topper, James Paul Rickey and Mitchell Gold. View Insider Buying and Selling for Alpine Immune Sciences.

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alpine Immune Sciences' stock price today?

One share of ALPN stock can currently be purchased for approximately $5.00.

How big of a company is Alpine Immune Sciences?

Alpine Immune Sciences has a market capitalization of $92.85 million and generates $700,000.00 in revenue each year. The biotechnology company earns $-36,490,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. Alpine Immune Sciences employs 48 workers across the globe.View Additional Information About Alpine Immune Sciences.

What is Alpine Immune Sciences' official website?

The official website for Alpine Immune Sciences is http://www.nivalis.com/.

How can I contact Alpine Immune Sciences?

Alpine Immune Sciences' mailing address is 201 Elliott Avenue West Suite 230, Seattle WA, 98119. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected]


MarketBeat Community Rating for Alpine Immune Sciences (NASDAQ ALPN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  284 (Vote Outperform)
Underperform Votes:  301 (Vote Underperform)
Total Votes:  585
MarketBeat's community ratings are surveys of what our community members think about Alpine Immune Sciences and other stocks. Vote "Outperform" if you believe ALPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALPN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel